TechBio Boost: shaping the future of healthcare
In this blog, Ethan Almond, Content & Communications Executive at the BioIndustry Association (BIA), reflects on the successes of the 2025 TechBio Boost cohort. He notes that the programme takes on founders and entrepreneurs working at the intersection of biology, data and cutting-edge computation – guiding and connecting them to people and organisations that will be crucial to their success.
TechBio’s potential to both transform our sector and provide precision diagnosis and care to patients is well recognised, and TechBio Boost is playing a vital role in scaling companies in this space. The programme takes on founders and entrepreneurs working at the intersection of biology, data and cutting-edge computation – guiding and connecting them to people and organisations that will be crucial to their success. 2025 brought together the second diverse cohort of companies building from Seed stage towards Series A, giving them the support they need to scale their businesses.
Developed and managed by BIA and KQ Labs and supported by London & Partners’ Grow London Early Stage programme, TechBio Boost has cemented its role in shaping the next generation of TechBio leaders. Over the course of the year, the second cohort accessed world-class mentoring, investor and pharma engagement and flagship community events – all carefully designed to help founders sharpen their strategies, build high-impact networks and accelerate their path to market.
Case studies
Queen Square Analytics
Queen Square Analytics
Queen Square Analytics (QSA) develops and applies advanced imaging analysis to neurological conditions. Before joining TechBio Boost, the company faced challenges generating enough margin, profit and funding to invest in the translation, commercialisation and ongoing development of its core innovations.
The programme provided QSA with the mentoring and networking it needed to support its initiative to commercialise a “key piece of technology”. The support allowed it to craft a business proposition and start the process to seek additional support in this venture. QSA’s plans for future are to expand to adjacent neurological conditions from its current remit, secure larger clinical trial work and commercialise imaging applications for clinical use.
TechBio Boost provides the catalytic impetus to move forward an initiative that had been stuck for lack of resources and new ideas. Our time with the programme has focused our plans and proposition as well as provided us with opportunities for making them happen.
Kiin Bio
Kiin Bio
Kiin Bio is a company building its KiinOS Platform to transform drug discovery. The unified system brings together intelligent virtual scientists, an agentic marketplace and scalable infrastructure to accelerate every stage of the R&D process, from literature review and bioinformatics to experimental design and wet-lab execution.
Before joining, the business had recently closed its pre-seed funding round ($2.2M) and had two main priorities – to grow its client pipeline and build its team. Kiin Bio described the TechBio Boost programme as “invaluable” – benefitting from direct one-to-one access to highly experienced industry leaders, as well as from engaging, well-curated networking events – such as TechBio UK – that generated genuine new commercial opportunities for the fast-growing UK start-up.
The company found the two-day retreat with current and past cohort members particularly impactful, enabling it to build “strong, lasting relationships with like-minded peer organisations that continue to support us on our growth journey”. Concluding the programme at the Demo Day held at the Crick Institute helped Kiin Bio to refine its pitch and establish new relationships with investors, an important step as it prepares to fundraise in 2026. As a result of TechBio Boost, Kiin Bio will now be looking to raise funds sooner than previously planned to support existing UK/EU client growth and US expansion.
The TechBio Boost programme has been invaluable to Kiin Bio. Direct one-to-one access to highly experienced industry leaders, alongside well-curated networking events such as TechBio Boost Retreat, Demo Day and TechBio UK, has helped us build a strong and supportive network and generated genuine new commercial opportunities for our fast-growing UK start-up. We would highly recommend the programme to any growth-stage TechBio company.
Enhanced Fertility
Enhanced Fertility
Enhanced Fertility is a healthtech company building digital and AI-powered infrastructure for reproductive healthcare. It connects scattered clinical data, reduces missed and delayed diagnoses and empowers clinicians and patients with clear, personalised, evidence-based fertility care.
Before joining TechBio Boost, Enhanced Fertility validated a software to automate diagnosis of fertility conditions. To bring it to market, it had to complete several tasks:
US regulatory readiness and pilot launch:
- finalise EnhancedDx technical file with new diagnostic modules (anatomical, lifestyle)
- initiate pilot with selected US lab partners to validate outsourced testing workflows
- prepare and submit pre-submission or 510(k) documentation for FDA.
IP and product asset protection:
- prepare and file two priority patent applications based on IP audit
- develop freedom-to-operate summary to support investor and acquirer discussions.
US market and investor entry strategy:
- close current financing round with focus on US-based investors
- develop go-to-market playbook targeting 5 high-fit fertility clinics and 1 EHR partner
- engage potential strategic acquirers (EHR, pharma, or provider networks) to align exit pathway.
On TechBio Boost, Enhanced Fertility received one-to-one support, which it found helpful in adjusting the pitch deck for investor meetings. The company also received advice about US market entry. As a result of the programme, Enhanced Fertility incorporated in the US, has tests available across 50 US states through 16 lab collaborations, is discussing pilots with two hospitals in the US, raised investment and prepared documentation for medical device registration.
In the short term, Enhanced Fertility will expand partnerships with fertility clinics and laboratory networks to embed our software as the clinical operating system for patient onboarding, diagnostics and treatment readiness. The company will continue validating its AI models through clinical studies to strengthen evidence and regulatory readiness.
In the medium term, Enhanced Fertility plans to scale internationally by localising the platform for new markets and languages, integrating with national health systems and clinic management software. And in the long term, the company aims to build the leading data infrastructure for reproductive health, enabling earlier diagnosis, personalised treatment pathways and population-level insights that improve fertility outcomes globally.
TechBio Boost has been instrumental in accelerating our path from clinical insight to scalable product. The programme has strengthened our strategy, expanded our network across healthtech and life sciences, and supported us in translating validated clinical research into deployable software for fertility clinics. It has directly contributed to our readiness to scale Enhanced Fertility internationally.
Shaping the future of healthcare
TechBio Boost 2025 demonstrates the UK’s growing strength in convergent science. It is where machine learning, computational biology, robotics and biosolutions meet to shape the future of healthcare. The programme is more than a training ground; it is an engine for scaling globally competitive companies and cultivating a thriving community of innovators.
With 2025’s cohort now forging ahead – raising investment, forming partnerships and accelerating breakthrough science – the programme continues to deepen its impact across the TechBio landscape. At BIA, we will continue to celebrate the founders, mentors, partners and champions who make our sector impactful to patients and the country at large – onwards to TechBio in 2026 and beyond!
